StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$26.62−0.90 (-3.27%)

Close on Nov 18, 2026Market cap $2.97BP/E –Yield –

Amylyx Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Amylyx Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$123.48M. For fiscal 2025 it was -$123.48M. The highest annual figure on record is $10.68M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$123.48M–
FY2024Dec 31, 2024-$167.80M-1671.5%
FY2023Dec 31, 2023$10.68M–
FY2022Dec 31, 2022-$182.40M–
FY2021Dec 31, 2021-$75.15M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$27.99M–
Q3 FY2025Sep 30, 2025-$30.39M–
Q2 FY2025Jun 30, 2025-$25.27M–
Q1 FY2025Mar 31, 2025-$39.84M–
Q4 FY2024Dec 31, 2024-$59.03M-547.4%
Q3 FY2024Sep 30, 2024-$41.55M–
Q2 FY2024Jun 30, 2024-$66.67M-900.3%
Q1 FY2024Mar 31, 2024-$556.00K–
Q4 FY2023Dec 31, 2023$13.20M–
Q3 FY2023Sep 30, 2023-$5.53M–
Q2 FY2023Jun 30, 2023$8.33M–
Q1 FY2023Mar 31, 2023-$5.32M–
Q4 FY2022Dec 31, 2022-$50.32M–
Q3 FY2022Sep 30, 2022-$43.54M–
Q2 FY2022Jun 30, 2022-$47.57M–
Q1 FY2022Mar 31, 2022-$40.98M–
Q4 FY2021Dec 31, 2021-$28.43M–
Q3 FY2021Sep 30, 2021-$21.02M–
Q2 FY2021Jun 30, 2021-$13.05M–
Q1 FY2021Mar 31, 2021-$12.66M–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?